Hepatit B

Publicerad 2021-01-16

OBS! Engelsk text.

Hepatitis B - Pipeline Review, H2 2020

The Pharmaceutical and Healthcare latest pipeline guide Hepatitis B - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Hepatitis B (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting and abdominal pain. Risk factors include age, severe kidney disease, haemophilia, share needles during drug use and born to a hepatitis-b infected mother. Treatment includes antiviral drugs.

For more information please click on:
Hepatitis B - Pipeline Review, H2 2020

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis B (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Hepatitis B (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hepatitis B (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hepatitis B (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Hepatitis B (Infectious Disease)

Reasons to Buy:
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hepatitis B (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hepatitis B (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned:
- Abhelix LLC
- Ai-biopharma SAS
- AiCuris GmbH & Co KG
- AIMM Therapeutics BV
- Akshaya Bio Inc
- Aligos Therapeutics Inc
- AlloVir Inc
- AlphaMab Co Ltd
- Alphamab Oncology
- Altimmune Inc
and many more.


Publicerad 2020-11-29

OBS! Engelsk text.

Chronic Hepatitis B Virus - Epidemiology Forecast to 2030.

Hepatitis B is the most common serious liver infection in the world. It is caused by the hepatitis B virus that attacks and injures the liver. Millions of people are living with a chronic hepatitis B infection all around the world. The hepatitis B virus (HBV) is transmitted through blood and infected bodily fluids. It can be passed to others through direct contact with blood, unprotected sex, use of illegal drugs, unsterilized or contaminated needles.

HBV is most commonly spread through sexual contact, accounting for nearly two-thirds of acute HBV cases. It is considered as a “silent epidemic” because most people do not have symptoms when they are newly infected or chronically infected. Thus, they can unknowingly spread the virus to others and continue the silent spread of hepatitis B. Most hepatitis B infections clear up within 1-2 months without treatment. When the infection lasts more than 6 months, it can develop into chronic hepatitis B, which can lead to chronic inflammation of the liver, cirrhosis (scarring of the liver), liver cancer, and/or liver failure. HBV infection has been identified as an important cause of chronic hepatitis (35.9%) and liver cirrhosis (44.2%).

For more information please click on:
Chronic Hepatitis B Virus - Epidemiology Forecast to 2030

The symptoms of hepatitis B include fatigue, poor appetite, stomach pain, fever, nausea, vomiting, and occasionally joint pain, hives, or rash. Urine may become darker in colour, and then jaundice (yellowing of the skin and whites of the eyes) may appear. Adults are more likely than children to develop symptoms; however, up to 50% of adults who have the acute infection do not have any symptoms. The symptoms may appear within 6 weeks to 6 months after exposure, but usually 4 months. The virus can be found in blood and other body fluids several weeks before symptoms appear and generally persists for several months afterwards.

This condition is diagnosed with blood tests, which are also used to monitor its effects on the liver. For chronic cases, a liver biopsy may be needed. A biopsy is the removal of a sample of liver tissue for testing.

Key Questions Answered:

- What will be the growth opportunities in the 7MM with respect to the patient population pertaining to CHB?
- What are the key findings pertaining to the CHB epidemiology across the 7MM and which country will have the highest number of patients during the study period (2017-2030)?
- What would be the total number of patients of CHB across the 7MM during the study period (2017-2030)?
- Among the EU5 countries, which country will have the highest number of patients during the study period (2017-2030)?
- At what CAGR the patient population is expected to grow in the 7MM during the study period (2017-2030)?
- What are the various recent and upcoming events which are expected to improve the diagnosis of CHB?

In light of the current Covid-19 Pandemic, it may be possible to have this report customised.

To order online, please click here. If you require any assistance, feel free to contact me.

Thank you for your consideration.

Best Regards,

David Murphy
Senior Manager
Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland.

  Den här webbplatsen använder cookies för att alla funktioner och tjänster ska fungera, samt förbättra användarvänligheten.